TMO
Thermo Fisher Scientific Inc.
Revenue by segment
2025, ended Dec 31, 2025
Earlier:
Segments by fiscal year
| USDLine, in USD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laboratory Products and Biopharma Services | 23.8B | 23.0B | 22.9B | 22.3B | 14.9B | 12.2B | 10.6B | 10.0B | 7.8B | 6.7B | 6.4B | 6.6B | 6.4B | — | — | — | — | — |
| Life Sciences Solutions | 8.8B | 8.2B | 8.5B | 11.6B | 15.6B | 12.2B | 6.9B | 6.3B | 5.7B | 5.3B | 4.8B | 4.2B | 713M | 659M | — | — | — | — |
| Analytical Instruments | 7.35B | 7.27B | 7.10B | 6.44B | 6.07B | 5.12B | 5.52B | 5.47B | 4.82B | 3.67B | 3.21B | 3.25B | 3.15B | 3.11B | 3.74B | 3.24B | 2.92B | 4.47B |
| Specialty Diagnostics | 4.60B | 4.45B | 4.32B | 4.60B | 5.66B | 5.34B | 3.72B | 3.72B | 3.49B | 3.34B | 3.24B | 3.34B | 3.19B | 2.96B | 2.47B | 2.15B | 2.15B | — |
| Segment Reconciling Items | 2.03B | 1.89B | 1.83B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Elimination of intersegment revenues | −2.03B | −1.89B | −1.83B | — | −3.01B | −2.66B | −1.15B | −1.14B | −0.94B | −0.77B | −0.63B | −0.50B | −0.37B | −0.33B | −0.48B | −0.47B | −0.40B | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | 6.10B | 5.83B | 5.47B | 5.24B | 6.03B | |
| Laboratory Products and Services | — | — | — | — | — | — | — | — | — | — | — | — | — | 6.10B | 5.83B | 5.47B | 5.24B | 6.46B |
| Intersegment Eliminations | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | −426M |
| Total | 44.6B | 42.9B | 42.9B | 44.9B | 39.2B | 32.2B | 25.5B | 24.4B | 20.9B | 18.3B | 17.0B | 16.9B | 13.1B | 12.5B | 11.6B | 10.4B | 9.9B | 10.5B |